Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Acquires 10,000 Shares

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. purchased 10,000 shares of the stock in a transaction that occurred on Friday, January 17th. The shares were purchased at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the purchase, the director now directly owns 922,334 shares of the company’s stock, valued at approximately $2,370,398.38. This trade represents a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Anixa Biosciences Stock Down 6.6 %

Shares of ANIX opened at $2.41 on Friday. The company has a 50-day moving average price of $2.80 and a two-hundred day moving average price of $3.02. The stock has a market cap of $77.59 million, a price-to-earnings ratio of -6.18 and a beta of 0.90. Anixa Biosciences, Inc. has a 12 month low of $2.07 and a 12 month high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. Equities research analysts expect that Anixa Biosciences, Inc. will post -0.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ANIX has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday.

Institutional Investors Weigh In On Anixa Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the company. International Assets Investment Management LLC increased its position in shares of Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares in the last quarter. Westside Investment Management Inc. grew its stake in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after buying an additional 21,100 shares during the last quarter. Tyler Stone Wealth Management increased its holdings in shares of Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after buying an additional 21,008 shares in the last quarter. Concorde Asset Management LLC bought a new position in shares of Anixa Biosciences in the second quarter valued at approximately $31,000. Finally, Virtu Financial LLC acquired a new position in shares of Anixa Biosciences in the 3rd quarter worth approximately $34,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.